公开(公告)号：US20210230299A1

公开(公告)日：2021-07-29

申请号：US17136483

申请日：2020-12-29

Applicant: Dyax Corp.

Inventor： Shauna Mason ,  Jon A. Kenniston ,  Andrew Nixon ,  Daniel J. Sexton ,  Stephen R. Comeau ,  Burt Adelman

IPC: C07K16/36

Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

公开(公告)号：US20180118851A1

公开(公告)日：2018-05-03

申请号：US15541066

申请日：2015-12-31

Applicant: Dyax Corp.

Inventor： Stephen R. Comeau ,  Andrew Nixon ,  Niksa Kastrapeli ,  Jon A. Kenniston ,  Gregory P. Conley ,  Shauna Mason ,  Allison P. Lindberg ,  Kristopher Kopacz ,  Burt Adelman

IPC: C07K16/40 ,  C07K16/36 ,  C12N9/64 ,  A61K39/395

CPC classification number: C07K16/40 ,  A61K39/395 ,  A61P7/02 ,  C07K16/36 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/94 ,  C12N9/64

Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis. One aspect of the present disclosure is a bispecific antibody, comprising: a first polypeptide that comprises a light chain of a first antibody, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL) (e.g., a kappa light chain or a lambda light chain); and a second polypeptide that comprises a heavy chain of the first antibody, the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH).

公开(公告)号：US20190185580A1

公开(公告)日：2019-06-20

申请号：US16199453

申请日：2018-11-26

Applicant: Dyax Corp.

Inventor： Andrew Nixon ,  Jon A. Kenniston ,  Stephen R. Comeau

IPC: C07K16/40

CPC classification number: C07K16/40 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

公开(公告)号：US10913802B2

公开(公告)日：2021-02-09

申请号：US15746048

申请日：2016-07-21

Applicant: Dyax Corp.

Inventor： Shauna Mason ,  Jon A. Kenniston ,  Andrew Nixon ,  Daniel J. Sexton ,  Stephen R. Comeau ,  Burt Adelman

IPC: C07K16/36 ,  A61K39/00 ,  A61P7/02 ,  A61P9/00 ,  A61P11/00

Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

公开(公告)号：US20190002584A1

公开(公告)日：2019-01-03

申请号：US15746048

申请日：2016-07-21

Applicant: Dyax Corp.

Inventor： Shauna Mason ,  Jon A. Kenniston ,  Andrew Nixon ,  Daniel J. Sexton ,  Stephen R. Comeau ,  Burt Adelman

IPC: C07K16/36

Abstract: Disclosed herein are anti-Factor Xlla antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.